Clinical TrialHighlighted
MHID-9688108PMID: 309827482019Clinics and Research in Hepatology and Gastroenterology
Darinka Korovljev, Valdemar Stajer, Jelena Ostojic, Tyler W. LeBaron, Sergej M Ostojic
Background and aims: While non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide, its treatment remains elusive. Since metabolic impairment plays a major role in NAFLD pathogenesis, any pharmaceuticals, such as molecular hydrogen (H2), that advance lipid and glucose metabolism could be appropriate to tackle this complex condition. The aim of this stu
Clinical Trial
MHID-9868845PMID: 285605192018Irish Journal of Medical Science
D. Korovljev, T. Trivic, P. Drid, S. M. Ostojic
Background: Molecular hydrogen (H2) effectively treats obesity-related disorders in animal models, yet no studies have investigated the effectiveness and safety of H2 for improving biomarkers of obesity in humans.
Aim: In this double blind, placebo-controlled, crossover pilot trial, we evaluated the effects of H2 intervention on body composition, hormonal status, and mitochondrial function in ten
Animal StudyHighlighted
MHID-3385882PMID: 238115542013Biological & Pharmaceutical Bulletin
Rosa Mistica Coles Ignacio, Tae-Young Kang, Cheol-Su Kim, Soo-Ki Kim, Young-Chul Yang, Joon-Hyung Sohn, et al.
Whether or not alkaline reduced water (ARW) has a positive effect on obesity is unclear. This study aims to prove the positive effect of ARW in high-fat (HF) diet-induced obesity (DIO) in C57BL/6 mice model. Toward this, obesity was induced by feeding the C57BL/6 male mice with high-fat diet (w/w 45% fat) for 12 weeks. Thereafter, the animals were administered with either ARW or tap water. Next, t
